Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for ondansetron, the scientific conclusions are as follows:

In view of available data on myocardial ischemia (MI) from the literature, and spontaneous case reports showing a close temporal relationship, a positive de-challenge (observed after withdrawal and/or dose reduction) and in view of a plausible mechanism of action, the Lead Member State considers a causal relationship between ondansetron and MI at least a reasonable possibility. The Lead Member State concluded that the product information of products containing ondansetron should be amended accordingly.

The CMDh agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for ondansetron the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing ondansetron is unchanged subject to the proposed changes to the product information.

The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing ondansetron are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text **underlined and in bold**, deleted text ~~strike through~~)

Summary of Product Characteristics

Section 4.4

A warning should be added as follows:

Cases of myocardial ischemia have been reported in patients treated with ondansetron. In some patients, especially in the case of intravenous administration, symptoms appeared immediately after administration of ondansetron. Patients should be alerted to the signs and symptoms of myocardial ischaemia.

Section 4.8:

ADRs should be added as follows:

Cardiac disorders: **myocardial ischemia (frequency unknown) (see section 4.4)**

Package Leaflet

Part 4

Myocardial ischemia

Signs include:

- **sudden chest pain or**
- **chest tightness**

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	November 2021 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	26 December 2021
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	24 February 2022